Paper
0
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Authors
Published
Oct 20, 2018
Show more
Save
Tip0
TipSave
Abstract
Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is an aggressive disease with poor outcomes. Nanoparticle albumin-bound (nab)–paclitaxel may enhance the anticancer activity of atezolizumab.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.